Repurposing of Anti-Infectives for the Management of Onchocerciasis Using Machine Learning and Protein Docking Studies

利用机器学习和蛋白质对接研究重新利用抗感染药物治疗盘尾丝虫病

阅读:1

Abstract

There is a need to improve the discovery of new drugs for neglected tropical diseases (NTDs), as the lack of financial incentives has slowed their development. Currently, ivermectin and moxidectin are used in the management of onchocerciasis. We present a proof-of-concept study based on computational methods to find anti-infectives that can be repurposed or serve as lead compounds for onchocerciasis. A combination of exploratory data analysis, machine learning (ML), and molecular docking studies was used to evaluate 58 anti-infective agents. Out of the 58 test drugs, 14 were predicted by at least 5 ML models to be potentially useful in managing onchocerciasis. Molecular docking studies with the 14 predicted drugs using glutamate-gated chloride channel, a known target of ivermectin, an onchocerciasis drug, yielded good results. Cridanimod, diminazene, and vandetanib were the top 3 agents showing the highest binding affinities of -7.8, -7.2, and 7.1 kcal/mol, respectively, higher than the native ligand glutamate, which has a value of -4.5 kcal/mol. The binding interactions of these agents also showed overlaps with that of doramectin and pyrvinium agents that have demonstrated activity against onchocerciasis and ivermectin, the gold standard for onchocerciasis management. This study highlights the potential of cridanimod, diminazene, and vandetanib as promising candidates for developing new treatments for onchocerciasis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。